Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, and will now pause its development.
JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company with a market capitalization of $40.39 million, has announced a strategic partnership with Zina ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback